Chiusura precedente | 15,98 |
Aperto | 0,00 |
Denaro | 0,00 x N/D |
Lettera | 0,00 x N/D |
Min-Max giorno | 0,00 - 0,00 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | N/D |
Capitalizzazione | 4,354M |
Beta (5 anni mensile) | 0,58 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,36 |
Prossima data utili | 22 feb 2023 - 27 feb 2023 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023. “2023 is setting up to be an incredibly exciting year for Aclaris with several important expected data read-outs for our two lead clinical programs, zunsemetinib (ATI-450) and ATI-1777,” stated Douglas Manion, M.D., Aclaris’ Chief Executive
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-sta